(S (NP-SBJ-COOD (NP (JJ Acetylsalicylic) (NN acid)) (CC and) (NP (NN sodium) (NN salicylate))) (VP (VBP inhibit) (NP (NP-COOD (NP (JJ LPS-induced) (NN NF-kappa) (NN (c-Rel B)) (JJ nuclear) (NN translocation)) (, ,) (CC and) (NP (NP (NN synthesis)) (PP (IN of) (NP-COOD (NP (NP (NN tissue) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TF)) (-RRB- -RRB-))) (CC and) (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alfa)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))))))) (PP (IN in) (NP (JJ human) (NNS monocytes))))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP-COOD (NP (JJ acetylsalicylic) (NN acid)) (CC and) (NP (NN sodium) (NN salicylate)))) (PP (IN on) (NP (NP-COOD (NP (NP (DT the) (JJ LPS-induced) (NN synthesis)) (PP (IN of) (NP-COOD (NP (DT the) (JJ pro-coagulant) (NN protein) (NP (NP (NN tissue) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TF)) (-RRB- -RRB-)))) (CC and) (NP (DT the) (JJ pro-inflammatory) (NN protein) (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (DT the) (NN prostaglandin) (NN PGE2))) (PP (IN in) (NP (JJ human) (NNS monocytes)))))))) (. .))
(S (NP-SBJ (DT Both) (NNS drugs)) (ADVP (RB dose-dependently)) (VP-COOD (VP (VBD inhibited) (NP (NP (JJ LPS-induced) (NP-COOD (NP (NN TF)) (CC and) (NP (NN TNF-alpha))) (NN synthesis)) (PP (IN at) (NP (NP-COOD (NP (DT the) (NN mRNA) (NP (-NONE- *RNR*-32))) (CC and) (NP (DT the) (NN protein) (NP (-NONE- *RNR*-32)))) (NP-32 (NN level)))))) (, ,) (CC and) (VP (VBD reduced) (NP (NN PGE2) (NN production)))) (. .))
(S (SBAR (IN As) (S (NP-SBJ-33 (-NONE- *)) (VP (VBN evidenced) (NP (-NONE- *-33)) (PP (IN by) (NP-LGS-COOD (NP (NP (NN electro) (NN mobility) (NN shift) (NN assay)) (PRN (-LRB- -LRB-) (NP (NN EMSA)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT a) (NN NF-kappa) (NN B) (JJ prototypic) (NN probe))))))))) (, ,) (NP-SBJ (DT these) (NNS drugs)) (ADVP (RB probably)) (VP (VBP exert) (NP (PRP$ their) (JJ inhibitory) (NNS effects)) (PP (IN by) (NP (NP (NN interference)) (PP (IN with) (NP (NP (DT the) (JJ nuclear) (NN translocation)) (PP (IN of) (NP (NN NF-kappa) (NN (c-Rel B)) (NNS proteins)))))))) (. .))
(S (NP-SBJ (DT These) (NNS data)) (VP (MD may) (VP (VB expand) (NP (NP (DT the) (NN understanding)) (PP (IN of) (NP (NP (DT the) (ADJP-COOD (ADJP (JJ anti-thrombotic)) (CC and) (ADJP (JJ anti-inflammatory))) (NNS effects)) (PP (IN of) (NP (DT these) (NNS drugs))) (SBAR-TMP (WHADVP-34 (WRB when)) (S (NP-SBJ (NP (NN activation)) (PP (IN of) (NP (NNS monocytes)))) (VP (VBZ occurs) (ADVP (-NONE- *T*-34)))))))))) (. .))
